CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO
Cannabinoids Enhance Radiation Efficacy for Cancer, Study Shows
Researchers from St George’s University, London have published a study that suggests cannabinoids may enhance the therapeutic efficacy of cancer radiation therapy. They discovered that radiotherapy combined with administration of cannabidiol (CBD) and tetrahydrocannabinol (THC) significantly reduced the growth of brain tumor (glioma) cells in mice. The study appeared in the November 14, 2014, on-line edition of the journal Molecular Cancer Therapeutics (The Combination of Cannabidiol and Δ9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model).
 
In the study, mice injected with tumor cells received dosing of pure CBD and THC together with irradiation. After 21 days the size of tumors in mice that received combination CBD and THC treatment and irradiation were 7 to 9 fold less in size than tumors in mice that received only radiation treatment. Tumors of mice exposed to cannabinoids and irradiation were also found to have lower levels of growth and vascularization markers than observed in control groups.
 
The researchers speculate that CBD and THC, as well as other cannabinoids, improve radiation cancer therapy by interfering with cellular repair mechanisms. They further speculate that cannabinoids inhibit cancer development by reducing the growth of new capillary blood vessels. “It is now important to expand this study to understand the biologic basis of this enhancement, particularly the suggestion that vascularization may be impeded,” the authors commented.
 
Cerilliant has been providing native and stable-isotope labeled solution-based Certified Reference Materials (CRMs) for over 30 years. Cerilliant’s broad offering of cannabinoid CRMs include hydroxy, carboxy, and glucuronide metabolites in addition to cannabinoids routinely analyzed by MS methods in clinical toxicology, urine drug testing, and forensic analysis applications. Cerilliant also offers a wide selection of cannabinoid solution CRMs for use in Cannabis potency testing and impurity profiling as well as pharmaceutical research. These reference solutions are produced and certified to the highest industry standards including ISO Guide 34 and ISO/IEC 17025 and are classified as "certified reference materials" in accordance with ISO requirements.
 
Cerilliant provides its certified solution standards of medicinal and other Schedule I cannabinoids in a US DEA and Health Canada (with TK #’s)-exempt solution format, allowing laboratories to place orders without additional regulatory paperwork. Our multiple ISO accreditations ensure that Cerilliant products and services meet the highest industry standards across international borders. Click on the link below to view our complete listing of cannabinoid Certified Spiking Solutions®:
 
 
 
 
 
 


Return to Article List


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn